Osteopontin and carotid atherosclerosis in patients with essential hypertension

被引:58
作者
Kurata, Mie [1 ]
Okura, Takafumi [1 ]
Watanabe, Sanae [1 ]
Fukuoka, Tomikazu [1 ]
Higaki, Jitsuo [1 ]
机构
[1] Ehime Univ, Sch Med, Dept Internal Med 2, Toon, Ehime 7910295, Japan
关键词
aldosterone; atherosclerosis; inflammation; carotid arteries; osteopontin; ultrasound;
D O I
10.1042/CS20060074
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
OPN (osteopontin), a pro-inflammatory cytokine, has recently emerged as a key factor in both vascular remodelling and the development of atherosclerosis. However, the relationship between OPN and atherosclerosis in patients without symptomatic cardiovascular. disease is not clear. Therefore we measured plasma OPN levels and evaluated the correlation between plasma OPN levels and atherosclerosis as target organ damage in patients with EHT (essential hypertension). Plasma OPN levels were measured in 76 patients with EHT using a solid-phase sandwich ELISA. IMT (intima-media thickness), and V-d and V-s (mean diastolic and systolic flow velocities respectively) were evaluated by carotid ultrasound. The V-d/V-s ratio, an index of peripheral arterial resistance, was also calculated. The patients were divided on the basis of median OPN levels into a high-OPN group and a low-OPN group. The mean IMT and aldosterone levels were higher (P = 0.024 and 0.031 respectively) and V-d/V-s was lower (P = 0.007) in the high-OPN group than in the low-OPN group. Plasma OPN levels were positively correlated with mean IMT (r = 0.308, P = 0.0068) and negatively with V-d/V-s (r = -0.293, P = 0.010). Stepwise regression analysis revealed that OPN was an independent determinant of mean IMT (P = 0.007) and V-d/V-s (P = 0.009), and aldosterone was an independent determinant of OPN. These results suggest that OPN plays a role in the development of atherosclerosis and may be a potential clinical marker for the prediction of atherosclerosis in patients with EHT.
引用
收藏
页码:319 / 324
页数:6
相关论文
共 31 条
[1]   Aldosteronism and peripheral blood mononuclear cell activation - A neuroendocrine-immune interface [J].
Ahokas, RA ;
Warrington, KJ ;
Gerling, IC ;
Sun, Y ;
Wodi, LA ;
Herring, PA ;
Lu, L ;
Bhattacharya, SK ;
Postlethwaite, AE ;
Weber, KT .
CIRCULATION RESEARCH, 2003, 93 (10) :E124-E135
[2]   EXPRESSION AND DISTRIBUTION OF OSTEOPONTIN IN HUMAN TISSUES - WIDESPREAD ASSOCIATION WITH LUMINAL EPITHELIAL SURFACES [J].
BROWN, LF ;
BERSE, B ;
VANDEWATER, L ;
PAPADOPOULOSSERGIOU, A ;
PERRUZZI, CA ;
MANSEAU, EJ ;
DVORAK, HF ;
SENGER, DR .
MOLECULAR BIOLOGY OF THE CELL, 1992, 3 (10) :1169-1180
[3]   THE NATURE AND SIGNIFICANCE OF OSTEOPONTIN [J].
BUTLER, WT .
CONNECTIVE TISSUE RESEARCH, 1989, 23 (2-3) :123-136
[4]   Development of atherosclerosis in osteopontin transgenic mice [J].
Chiba, S ;
Okamoto, H ;
Kon, S ;
Kimura, C ;
Murakami, M ;
Inobe, M ;
Matsui, Y ;
Sugawara, T ;
Shimizu, T ;
Uede, T ;
Kitabatake, A .
HEART AND VESSELS, 2002, 16 (03) :111-117
[5]   MOLECULAR-CLONING AND CHARACTERIZATION OF 2B7, A RAT MESSENGER-RNA WHICH DISTINGUISHES SMOOTH-MUSCLE CELL PHENOTYPES INVITRO AND IS IDENTICAL TO OSTEOPONTIN (SECRETED PHOSPHOPROTEIN-I, 2AR) [J].
GIACHELLI, C ;
BAE, N ;
LOMBARDI, D ;
MAJESKY, M ;
SCHWARTZ, S .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1991, 177 (02) :867-873
[6]  
Giachelli CM, 1998, AM J PATHOL, V152, P353
[7]   OSTEOPONTIN IS ELEVATED DURING NEOINTIMA FORMATION IN RAT ARTERIES AND IS A NOVEL COMPONENT OF HUMAN ATHEROSCLEROTIC PLAQUES [J].
GIACHELLI, CM ;
BAE, N ;
ALMEIDA, M ;
DENHARDT, DT ;
ALPERS, CE ;
SCHWARTZ, SM .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 92 (04) :1686-1696
[8]   ULTRASONIC EVALUATION OF EARLY CAROTID ATHEROSCLEROSIS [J].
HANDA, N ;
MATSUMOTO, M ;
MAEDA, H ;
HOUGAKU, H ;
OGAWA, S ;
FUKUNAGA, R ;
YONEDA, S ;
KIMURA, K ;
KAMADA, T .
STROKE, 1990, 21 (11) :1567-1572
[9]  
HIROTA S, 1993, AM J PATHOL, V143, P1003
[10]   OSTEOPONTIN MESSENGER-RNA IS EXPRESSED BY SMOOTH MUSCLE-DERIVED FOAM CELLS IN HUMAN ATHEROSCLEROTIC LESIONS OF THE AORTA [J].
IKEDA, T ;
SHIRASAWA, T ;
ESAKI, Y ;
YOSHIKI, S ;
HIROKAWA, K .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 92 (06) :2814-2820